Sugi Predict

Sugi Predict / Compounds / SCHEMBL499471

SCHEMBL499471

SCHEMBL499471

CCC(C)C(C(=O)O)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 2/20 0.61
▸ CHRM2 P08172 2/20 0.55
▸ CHRM4 P08173 2/20 0.55
▸ CHRM1 P11229 2/20 0.55
▸ CHRM3 P20309 2/20 0.55
▸ CHRM5 P08912 1/20 0.54
▸ SIGMAR1 Q99720 1/20 0.54
▸ KMT2A Q03164 3/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ LMNA P02545 5/20 0.47
▸ ACE P12821 1/20 0.45
▸ SRC P12931 1/20 0.45
▸ APAF1 O14727 1/20 0.44
▸ MAPK1 P28482 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4921518 1.00 CYP2D6 (0.61) CYP2D6CHRM2CHRM4CHRM1CHRM3
SCHEMBL23872457 1.00 CYP2D6 (0.61) CYP2D6CHRM2CHRM4CHRM1CHRM3
SCHEMBL2644175 0.85 CHRM2 (0.52) CYP2D6CHRM2CHRM4CHRM1CHRM3
SCHEMBL6237736 0.85 CYP2D6 (0.57) CYP2D6CHRM2CHRM4CHRM1CHRM3
SCHEMBL517640 0.85 ACHE (0.43) CYP2D6CHRM2CHRM4CHRM1CHRM3
SCHEMBL10443302 0.85 CHRM2 (0.52) CYP2D6CHRM2CHRM4CHRM1CHRM3
SCHEMBL28171482 0.84 CYP2D6 (0.61) CYP2D6CHRM2CHRM4CHRM1CHRM3
SCHEMBL31686418 0.83 FFAR2 (0.49) CYP2D6CHRM2CHRM4CHRM1CHRM3
SCHEMBL11576841 0.83 UGT2B7 (0.51) CYP2D6KMT2AMEN1ACE
SCHEMBL27889239 0.82 CYP2D6 (0.59) CYP2D6CHRM2CHRM4CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 — — EP claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 — — WO claimed
CN-114790136-A Preparation method and application of active trivalent organic chromium compound 中国石油天然气股份有限公司 2022-07-26 — — CN claimed
US-11181519-B2 System and method for differential diagnosis of diseases TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2021-11-23 — — US claimed
US-20190271685-A1 SYSTEM AND METHOD FOR DIFFERENTIAL DIAGNOSIS OF DISEASES TECHNION RESEARCH & DEVLOPMENT FOUNDATION LIMITED (IL) 2019-09-05 — — US claimed
CN-109791140-A The system and method for difference diagnosis for disease 泰克年研究发展基金会公司 2019-05-21 — — CN claimed
EP-3472613-A1 SYSTEM AND METHOD FOR DIFFERENTIAL DIAGNOSIS OF DISEASES Technion Research & Development Foundation Ltd. (IL) 2019-04-24 — — EP claimed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 — — US claimed
WO-2017216794-A1 SYSTEM AND METHOD FOR DIFFERENTIAL DIAGNOSIS OF DISEASES TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2017-12-21 — — WO claimed
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES Indiana University Research and Technology Corpora tion (US) 2016-06-23 — — US claimed
WO-2009144725-A1 CARBON NANOTUBE STRUCTURES IN SENSOR APPARATUSES FOR ANALYZING BIOMARKERS IN BREATH SAMPLES TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2009-12-03 — — WO claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 — — US claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 — — US claimed
US-20060034731-A1 Sensor arrays for detecting analytes in fluids CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2006-02-16 — — US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 — — US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 — — US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 — — US claimed
US-20050256164-A1 NK1 and NK3 antagonists PFIZER INC 2005-11-17 — — US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 — — US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256164-A1 NK1 and NK3 antagonists TAC3, TACR1, TACR2 CYP2D6 3161/4885CHRM2 1963/4885CHRM4 1240/4885
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS CYP2D6 3079/4885CHRM2 4876/4885CHRM4 4813/4885
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS CYP2D6 3079/4885CHRM2 4876/4885CHRM4 4813/4885
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 CYP2D6 1222/4885CHRM2 31/4885CHRM4 44/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 CYP2D6 1122/4885CHRM2 3915/4885CHRM4 4184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.